A yeast two-hybrid technology-based system for the discovery of PPARγ agonist and antagonist

Analytical Biochemistry

Volumn 335, Issue 2, 2004, Pages 253-259

  Chen, Qing ^a   Chen, Jing ^a   Sun, Tao ^a   Shen, Jianhua ^a   Shen, Xu ^a   Jiang, Hualiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Agonist; Antagonist; CREP binding protein (CBP); Peroxisome proliferator activated receptor (PPAR ); Yeast two hybrid; Galactosidase

Indexed keywords

CYTOLOGY; DIAGNOSIS; GENES; HYBRID SYSTEMS; LIGANDS; PROTEINS;

AGONIST; ANTAGONIST; BINDING PROTEINS; GALACTOSIDASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; YEAST TWO HYBRID;

YEAST;

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; BETA GALACTOSIDASE; BINDING PROTEIN; FARGLITAZAR; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PIOGLITAZONE; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ASSAY; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HYBRID; IC 50; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPORTER GENE; YEAST;

EID: 8844225475     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2004.09.004     Document Type: Article

References (39)

1. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
2. G. Murphy, and G.J. Holder PPAR-? agonists: therapeutic role in diabetes, inflammation, and cancer Trends Pharmacol. Sci. 21 2000 469 474
3. Y. Kodera, K. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators J. Biol. Chem. 275 2000 33201 33204
4. Y. Wu, W.W. Chin, Y. Wang, and T.P. Burris Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor J. Biol. Chem. 278 2003 8637 8644
5. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 93 1998 229 240
6. B. Hulin, P.A. McCarthy, and E.M. Gibbs The glitazone family of antidiabetic agents Curr. Pharma. Des. 2 1996 85 102
7. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J. Biol. Chem. 270 1995 12953 12956
8. B.M. Spiegelman PPAR-γ: adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514
9. B.B. Lowell PPARγ: an essential regulator of adipogenesis and modulator of fat cell function Cell 99 1999 239 242
10. B.R. Henke, S.G. Blanchard, M.F. Brackeen, K.K. Brown, J.E. Cobb, J.L. Collins, W.W. Harrington Jr., M.A. Hashim, E.A. Hull-Ryde, I. Kaldor, S.A. Kliewer, D.H. Lake, L.M. Leesnitzer, J.M. Lehmann, J.M. Lenhard, L.A. Orband-Miller, J.F. Miller, R.A. Mook, Jr., S.A. Noble, W. Oliver Jr., D.J. Parks, K.D. Plunket, J.R. Szewczyk, and T.M. Willson N-(2-Benzoylphenyl)-l- tyrosine PPARγ agonists: I. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents J. Med. Chem. 41 1998 5020 5036
11. J.L. Collins, S.G. Blanchard, G.E. Boswell, P.S. Charifson, J.E. Cobb, B.R. Henke, E.A. Hull-Ryde, W.M. Kazmierski, D.H. Lake, L.M. Leesnitzer, J. Lehmann, J.M. Lenhard, L.A. Orband-Miller, Y. Gray-Nunez, D.J. Parks, K.D. Plunkett, and W.Q. Tong N- (2-Benzoylphenyl)-l-tyrosine PPARγ agonists: II. Structure-activity relationship and optimization of the phenyl alkyl ether moiety J. Med. Chem. 41 1998 5037 5054
12. J.E. Cobb, S.G. Blanchard, E.G. Boswell, K.K. Brown, P.S. Charifson, J.P. Cooper, J.L. Collins, M. Dezube, B.R. Henke, E.A. Hull-Ryde, D.H. Lake, J.M. Lenhard, W. Oliver Jr., J. Oplinger, M. Pentti, D.J. Parks, K.D. Plunket, and W.Q. Tong N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: III. Structure-activity relationship and optimization of the N-aryl substituent J. Med. Chem. 41 1998 5055 5069
13. J.M. Lehmann, J.M. Lenhard, B.B. Oliver, G.M. Ringold, and S.A. Kliewer Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs J. Biol. Chem. 272 1997 3406 3410
14. J.M. Malinowski, and S. Bolesta Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review Clin. Ther. 22 2000 1151 1168
15. N. Kubota, Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. Ishii, T. Sugiyama, K. Eto, Y. Tsubamoto, A. Okuno, K. Murakami, H. Sekihara, G. Hasegawa, M. Naito, Y. Toyoshima, S. Tanaka, K. Shiota, T. Kitamura, T. Fujita, O. Ezaki, S. Aizawa, and T. Kadowaki PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Mol. Cell 4 1999 597 609
16. P.D. Miles, Y. Barak, W. He, R.M. Evans, and J.M. Olefsky Improved insulin sensitivity in mice heterozygous for PPAR-γ deficiency J. Clin. Invest. 105 2000 287 292
17. S.S. Deeb, L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, J. Kuusisto, M. Laakso, W. Fujimoto, and J. Auwerx A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity Nat. Genet. 3 1998 284 287
18. K. Hara, T. Okada, K. Tobe, K. Yasuda, Y. Mori, H. Kadowaki, R. Hagura, Y. Akanuma, S. Kimura, C. Ito, and T. Kadowaki The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes Biochem. Biophys. Res. Commun. 271 2000 212 216
19. D. Altshuler, J.N. Hirschhorn, M. Klannemark, C.M. Lindgren, M.C. Vohl, J. Nemesh, C.R. Lane, S.F. Schaffner, S. Bolk, C. Brewer, T. Tuomi, D. Gaudet, T.J. Hudson, M. Daly, L. Groop, and E.S. Lander The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Nat. Genet. 26 2000 76 80
20. P.W. Young, D.R. Buckle, B.B. Cantello, H. Chapman, J.C. Clapham, P.J. Coyle, D. Haigh, R.M. Hindley, J.C. Holder, H. Kallender, A.J. Latter, K.W. Lawrie, D. Mossakowska, G.J. Murphy, L.R. Cox, and S.A. Smith Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma J. Pharmacol. Exp. Ther. 284 1998 751 759
21. G. Krey, O. Braissant, F.L. Horset, M. Perroud, E. Kalkhoven, M. Parker, and W. Wahli Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Mol. Endocrinol. 11 1997 779 791
22. J.S. Nicholsa, D.J. Parksa, T.G. Conslerb, and S.G. Blancharda Development of a scintillation proximity assay for peroxisome proliferator-activated receptorγ ligand binding domain Anal. Biochem. 257 1998 112 119
23. C.Y. Yu, L.L. Chen, H.B. Luo, J. Chen, F. Cheng, C.S. Gui, R.H. Zhang, J.H. Shen, K.X. Chen, H.L. Jiang, and X. Shen Binding analyses between human PPARγ-LBD and ligands surface plasmon resonance biosensor assay correlating with circular dichroic spectroscopy determination and molecular docking Eur. J. Biochem. 271 2004 386 397
24. D.P. McDonnell, E. Vegeto, and M.A.G. Gleeson Nuclear hormone receptors as targets for new drug discovery Biotechnology 11 1993 1256 1261
25. T. Taniguchi, J. Mizukami, Method for identifying or screening agonist and antagonist to PPAR, U.S. Patent 6,365,361 (2002)
26. R.D. Gietz, and R.A. Woods Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method Methods Enzymol. 350 2002 87 96
27. P.S. Lazo, A.G. Ochoa, and S. Gascon α-Galactosidase from Saccharomyces carlsbergensis, cellular localization, and purification of the external enzyme Eur. J. Biochem. 77 1977 375 382
28. J. Yanagisawa, Y. Yanagi, Y. Masuhiro, M. Suzawa, T. Toriyabe, K. Kashiwagi, M. Watanabe, M. Kawabata, K. Miyazono, and S. Kato Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators Science 283 1999 1317 1321
29. K. Eguchi, M. Ozawa, Y.S. Endoh, J. Nishikawa, T. Nishihara, K. Goto, and H. Yoshimura Validity test for a yeast two-hybrid assay to screen for estrogenic activity and its application to insecticides and disinfectants for veterinary use Bull. Environ. Contam. Toxicol. 70 2003 226 232
30. E. Dornstauder, E. Jisa, I. Unterrieder, L. Krenn, W. Kubelka, and A. Jungbauer Estrogenic activity of two standardized red clover extracts intended for large scale use in hormone replacement therapy J. Steroid Biochem. Mol. Biol. 78 2001 67 75
31. P.J. Boyle, A.B. King, L. Olansky, A. Marchetti, H. Lau, R. Magar, and J. Martin Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records Clin. Ther. 24 2002 378 396
32. C.G. Gegick, and M.D. Altheimer Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice Endocrinol. Pract. 7 2001 162 169
33. B. Rogers, A. Decottignies, M. Kolaczkowski, E. Carvajal, E. Balzi, and A. Goffeau The pleitropic drug ABC transporters from Saccharomyces cerevisiae J. Mol. Microbiol. Biotechnol. 3 2001 207 214
34. M. Adams, C.T. Montague, J.B. Prins, J.C. Holder, S.A. Smith, L. Sanders, J.E. Digby, C.P. Sewter, M.A. Lazar, V.K. Chatterjee, and S. O'Rahilly Activators of peroxisome proliferator-activated receptor-γ have depot-specific effects on human preadipocyte differentiation J. Clin. Invest. 100 1997 3149 3153
35. B. Lecka-Czernik, E.J. Moerman, D.F. Grant, J.M. Lehmann, S.C. Manolagas, and R.L. Jilka Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation Endocrinology 143 2002 2376 2384
36. N. Takahashi, T. Kawada, T. Yamamoto, T. Goto, A. Taimatsu, N. Aoki, H. Kawasaki, K. Taira, K.K. Yokoyama, Y. Kamei, and T. Fushiki Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor J. Biol. Chem. 277 2002 16906 16912
37. G. Castillo, R.P. Brun, J.K. Rosenfield, S. Hauser, C.W. Park, A.E. Troy, M.E. Wright, and B.M. Spiegelman An adipogenic cofactor bound by the differentiation domain of PPARγ EMBO J. 18 1999 3676 3687
38. L.M. Leesnitzer, D.J. Parks, R.K. Bledsoe, J.E. Cobb, J.L. Collins, T.G. Consler, R.G. Davis, E.A. Hull-Ryde, J.M. Lenhard, L. Patel, K.D. Plunket, J.L. Shenk, J.B. Stimmel, C. Therapontos, T.M. Willson, and S.G. Blanchard Function consequences of cysteine modifcation in the ligand binding sites of peroxisome proliferator activated receptors by GW9662 Biochemistry 41 2002 6640 6650
39. R.A. Gupta, J.A. Brockman, P. Sarraf, T.M. Willson, and R.N. DuBois Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells J. Biol. Chem. 276 2001 29681 29687